Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.
View/ Open
Date
2017-07-07ICR Author
Author
van Erp, AEM
Versleijen-Jonkers, YMH
Hillebrandt-Roeffen, MHS
van Houdt, L
Gorris, MAJ
van Dam, LS
Mentzel, T
Weidema, ME
Savci-Heijink, CD
Desar, IME
Merks, HHM
van Noesel, MM
Shipley, J
van der Graaf, WTA
Flucke, UE
Meyer-Wentrup, FAG
Type
Journal Article
Metadata
Show full item recordAbstract
In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) and CD8 in tumors of 208 sarcoma patients. Primary untreated osteosarcoma (n = 46), Ewing sarcoma (n = 32), alveolar rhabdomyosarcoma (n = 20), embryonal rhabdomyosarcoma (n = 77), synovial sarcoma (n = 22) and desmoplastic small round cell tumors (DSRCT) (n = 11) were examined immunohistochemically. PD-L1 expression was predominantly detected in alveolar and embryonal rhabdomyosarcomas (15% and 16%, respectively). In the alveolar subtype PD-L1 expression was associated with better overall, event-free and metastases-free survival. PD-1 expression on lymphocytes was predominantly seen in synovial sarcomas (18%). High levels of CD8+ lymphocytes were predominantly detected in osteosarcomas (35%) and associated with worse event-free survival in synovial sarcomas. Ewing sarcoma and DSRCTs showed PD-1 on tumor cells instead of on tumor infiltrating lymphocytes. Overall, expression and clinical associations were found to be subtype dependent. For the first time PD-1 expression on Ewing sarcoma (19%) and DSRCT (82%) tumor cells was described.
Collections
Research team
Clinical and Translational Sarcoma
Sarcoma Molecular Pathology
Language
eng
Date accepted
2017-06-27
License start date
2017-07-07
Citation
Oncotarget, 2017
Publisher
IMPACT JOURNALS LLC